FDA Approves Lonsurf Plus Avastin for Metastatic Colorectal Cancer

The Food and Drug Administration has approved the combination of Lonsurf and Avastin for patients with metastatic colorectal cancer previously treated with chemotherapies, an anti-VEGF therapy and, if RAS wild-type, an anti-EGFR therapy.

Related Keywords

Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Marwan Fakih ,Josep Tebernero ,Drug Administration ,Hebron University Hospital ,New England Journal ,Taiho Oncology ,News ,Colorectal Cancer ,